+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 46 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
O

Actively Recruiting

Researchers are conducting a large prospective, observational cohort study to evaluate the clinical impact of new Monoclonal Antibodies MAB in patients with B-cell Non-Hodgkin Lymphoma NHL treated in Italian clinical practice. The study focuses on collecting information about the use, feasibility, effectiveness, and both short- and long-term side effects of novel MABs that have been approved by the European Medicines Agency since 2020 and prescribed according to authorized indications in Italy. Participants will be divided into groups based on treatment indication, antibody type, and lymphoma subtype to allow detailed analysis. The study observes patients with B-cell NHL who have received at least one dose of a novel MAB either alone or in combination, as authorized for use in Italy. Both patients receiving first-line treatment and those with relapsed or refractory disease are included. Various cohorts and sub-cohorts will be analyzed to understand outcomes by indication, antibody type, and histological subtype, providing a comprehensive overview of these treatments in real-life settings. Participants will be followed for at least five years to assess outcomes such as overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and the incidence of early and late adverse events. Clinical data collection will include treatment details, safety monitoring, and long-term follow-up to evaluate both effectiveness and toxicity. The study spans several years, allowing researchers to capture extensive real-world evidence on novel MAB use in B-cell NHL.

Age: 18Years +All Genders
61 locations
I

Actively Recruiting

Researchers are conducting an observational, multicenter, prospective study to evaluate the effects of benralizumab in adult patients with severe eosinophilic asthma. The study focuses on assessing the achievement of partial and complete clinical remission as defined by the Severe Asthma Network in Italy SANI. It also aims to deepen understanding of benralizumabs immunological effects and contribute to knowledge about asthma pathophysiology while consolidating long-term safety data. Participants in this study are patients treated with benralizumab, administered as 30mg subcutaneous injections according to the approved prescribing information. The study observes patients who have started or are about to start benralizumab treatment within a specific timeframe around enrollment. This real-life study does not involve assigning treatments but follows patients receiving benralizumab in clinical practice. During the study, participants will be monitored over up to 24 months to track clinical remission rates, asthma exacerbations, lung function changes, asthma control test scores, and medication use. Various assessments including lung function tests and questionnaires will be collected at baseline and multiple time points throughout the follow-up. The study aims to provide detailed real-world data on benralizumabs role in managing severe eosinophilic asthma.

Age: 18Years +All Genders
28 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
O

Actively Recruiting

Researchers are studying the clinical and health outcomes of amivantamab-containing treatments for people with common EGFR-mutated advanced non-small cell lung cancer NSCLC. NSCLC is the most common type of lung cancer and can spread to other parts of the body. This observational study looks at how these treatments work in real-world clinical settings for patients with specific EGFR mutations. Participants include those with advanced NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations. Two groups are observed one receiving amivantamab combined with carboplatin and pemetrexed after previous therapy failure, and another receiving amivantamab with lazertinib as first-line treatment. No study drugs are provided data is collected from routine medical care. During the study, researchers collect data on treatment duration, progression-free survival, overall survival, adverse events, dose changes, and medication use for up to about 60 months. Quality of life is assessed using the SKINDEX and EORTC QLQ-C30 questionnaires. The study tracks how patients respond to treatment and monitors safety outcomes, with participation lasting several years.

Age: 18Years +All Genders
90 locations
O

Actively Recruiting

Researchers are evaluating patient satisfaction, effectiveness, and safety of the drug Atezolizumab given by subcutaneous injection in people treated for certain cancers in routine healthcare settings. This observational study includes participants with specific types of lung cancer and hepatocellular carcinoma who receive Atezolizumab according to approved indications without altering their usual treatment plans. Participants are grouped into cohorts based on their diagnosis, including early-stage non-small cell lung cancer NSCLC after surgery and chemotherapy, metastatic NSCLC, extensive-stage small cell lung cancer ES-SCLC, and advanced or unresectable hepatocellular carcinoma HCC. The treatment with Atezolizumab is administered by the participants doctor independently of study participation. Throughout the study, participants report their satisfaction with the subcutaneous therapy using questionnaires at specific treatment cycles, and their quality of life is assessed by standardized tools. Researchers monitor survival outcomes and adverse events for up to approximately 3.5 years. The study captures real-world data on treatment experiences and monitors safety and effectiveness during routine clinical care.

Age: 18Years +All Genders
92 locations
E

Actively Recruiting

Researchers are evaluating how well intranasal esketamine works alongside standard care to quickly reduce symptoms of major depressive disorder MDD in adolescents with acute suicidal thoughts or behaviors. The study compares esketamine plus comprehensive standard care to a psychoactive placebo plus standard care to understand its effectiveness and safety in this population. Participants will be randomly assigned to one of two groups receiving treatment twice weekly for 4 weeks. One group receives intranasal esketamine starting at 84 mg, possibly reduced to 56 mg based on investigator judgment, along with oral placebo. The other group receives oral midazolam and intranasal placebo following a similar dosing schedule. The study allows dose flexibility between 56 mg and 84 mg for esketamine during treatment. During the study, participants will be monitored through various assessments including depression rating scales and measures of suicidality at baseline, 24 hours after the first dose, and throughout the 25-day treatment period. Researchers will evaluate changes in depressive symptoms, suicidality severity, and quality of life. Safety and adherence will be carefully observed, with the study continuing until primary outcome evaluation and completion by 2031.

Age: 12Years - 17YearsAll GendersPhase 3
49 locations
O

Actively Recruiting

Researchers are studying adult patients with generalized myasthenia gravis gMG who are positive for acetylcholine receptor AChR antibodies. The study aims to gather real-world evidence from Italian clinical practice on how efgartigimod alfa affects clinical outcomes and patient-reported experiences in those treated for gMG. This observational study will follow patients over a total duration of up to 23 months. The study involves collecting primary data at a baseline visit and follow-up visits at 6 and 12 months after baseline. Researchers will also gather secondary data from medical charts covering the 12 months before baseline, including details on MG-related therapies, exacerbations, hospitalizations, and the patients medical history. The treatment with efgartigimod alfa is decided independently by the treating physician as part of routine care, not influenced by study participation. Participants will be monitored through clinical assessments and questionnaires measuring changes in MG-Activities of Daily Living MG-ADL scores and the percentage achieving minimal symptom expression MSE up to 12 months. Additional measures include quality of life, fatigue, anxiety and depression, sleep quality, and caregiver burden scores tracked over the same period. The study collects comprehensive data to understand disease experience and treatment impact, with safety and outcomes evaluated throughout the 23-month period.

Age: 18Years +All Genders
30 locations
E

Actively Recruiting

Researchers are evaluating GB-0895 as an add-on therapy for adolescents and adults with severe asthma that remains uncontrolled despite using inhaled corticosteroids and other asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the effectiveness and safety of GB-0895 in improving asthma outcomes. Participants will receive either GB-0895 or a placebo through subcutaneous injections every six months during the treatment period. The study includes a screening and run-in phase from weeks -5 to 0, a treatment phase lasting 52 weeks, and a follow-up phase lasting from week 52 to week 90. An optional open-label extension allows continued GB-0895 treatment from week 52 through week 142. During the study, participants will undergo various assessments including lung function tests, questionnaires about asthma symptoms and quality of life, and monitoring for asthma exacerbations and adverse events. Researchers will measure outcomes such as the annual rate of asthma exacerbations and changes in lung function over 52 weeks. Safety evaluations will continue throughout treatment and follow-up. The total participation duration may extend up to nearly three years if the optional extension is chosen.

Age: 12Years - 80YearsAll GendersPhase 3
158 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.

Age: 40Years - 80YearsAll GendersPhase 3
305 locations

1-10 of 46

1